Archive | Melanoma News

Tesco shoppers ‘appalled’ after summer product announcement

Supermarket giant Tesco has left some shoppers ‘shocked’ with its latest offer.

Read the full story

Posted in Melanoma News, Patients, Latest News

BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients

Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Screening and Identification of Key Biomarkers in Melanoma

Malignant melanoma is uncommon worldwide, accounting for only ?1% of all malignant tumors.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Vidutolimod/Nivolumab Under Evaluation in PD-1-Refractory Advanced Melanoma

The safety and efficacy of the combination of vidutolimod (CMP-001) and nivolumab (Opdivo) is currently under investigation in patients with PD-1–refractory advanced melanoma, as part of the ongoing phase 2 CMP-001-010 trial (NCT04698187).1

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest